NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Brent S. Rice as Chief Commercial Officer (CCO). Mr. Rice joins ArriVent with over 25 years of U.S. and global commercial experience in the biotechnology... Read More

Positive interim Phase 1b update underscores firmonertinib’s potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025 Dosed the first patient in the Phase 1 Study for ARR-217 (MRG007), a CDH17 targeted ADC, in gastrointestinal tumors Top-line firmonertinib monotherapy data from global pivotal FURVENT Phase 3 study for first-line EGFR exon20 insertion mutant NSCLC... Read More

Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that topline firmonertinib monotherapy... Read More

NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the pricing of an underwritten public offering of 2,482,692 shares of its common stock at a price to the public of $19.50 per share and, in lieu of common stock to certain investors,... Read More

NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, $75 million of its shares of common stock and, in lieu of common stock to certain investors, pre-funded... Read More

16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients Robust central nervous system (CNS) activity; 41% (7/17) confirmed complete response (CR) and 53% confirmed overall response (ORR) in CNS evaluable disease patients by BICR in overall cohort Enrollment of first patient in a randomized, global pivotal Phase 3 (ALPACCA) study in... Read More

Virtual webinar on June 23, 2025 at 8:00 am ET NEWTOWN SQUARE, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the Company will host a virtual investor event to discuss the firmonertinib clinical program for the treatment of EGFR PACC... Read More

Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutations Planned update for development of firmonertinib in first-line NSCLC PACC mutations in Q2 2025 First IND for ARR-217 (MRG007), an antibody drug conjugate (ADC) targeting CDH17, submitted in China Cash, cash equivalents and marketable securities of $205.5 million as of March 31, 2025... Read More

NEWTOWN SQUARE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Merdad Parsey, M.D., Ph.D. to its Board of Directors. Dr. Parsey brings decades of executive experience leading global clinical development in the... Read More

First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC mutations Global pivotal Phase 3 monotherapy study for firmonertinib in first-line NSCLC harboring EGFR exon 20 insertion mutations achieved target enrollment Selected next-generation ADC candidate ARR-002 for IND enabling studies Cash and cash equivalents of $266.5 million as of December... Read More

Exclusive global license outside of Greater China for MRG007, a novel antibody drug conjugate (ADC) in development for gastrointestinal (GI) cancers First Investigational New Drug (IND) submission planned for 1H 2025 Expands ArriVent’s growing pipeline of next-generation ADCs NEWTOWN SQUARE, Pa. and SHANGHAI, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP) a clinical-stage... Read More

Robust firmonertinib monotherapy activity in front-line EGFR PACC mutant NSCLC including in patients with brain metastases Top-line pivotal data from global Phase 3 FURVENT trial for firmonertinib in front-line NSCLC harboring EGFR exon 20 insertion mutations expected 2025 Cash and cash equivalents of $282.9 million as of September 30, 2024 NEWTOWN SQUARE, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc.... Read More

81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases 90.9% (n = 20/22) of patients with confirmed responses remained on study with a median duration of response not yet reached at time of analysis ArriVent to host virtual webinar on these interim analyses of Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC on September 9, 2024 at 4:30 pm ET NEWTOWN SQUARE, Pa.,... Read More

Clinical proof-of-concept monotherapy data for once daily, first-line firmonertinib in EGFR PACC mutant non-small cell lung cancer (NSCLC) to be presented as a presidential symposium presentation at the 2024 World Conference on Lung Cancer (WCLC) ArriVent to host virtual webinar on these interim analyses of Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC in conjunction with 2024 WCLC on September 9, 2024 at 4:30pm... Read More

First-line monotherapy data for once daily firmonertinib selected as an oral presentation in the presidential session First prospectively designed randomized clinical data for a small-molecule EGFR tyrosine kinase inhibitor in PACC mutant non-small cell lung cancer patient population ArriVent to host virtual webinar in conjunction with 2024 WCLC NEWTOWN SQUARE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc.... Read More

Collaboration will leverage Alphamab’s antibody drug conjugate (“ADC”) research and discovery platform and ArriVent’s global development and commercialization expertise Upfront and milestone payments to Alphamab worth up to $615.5 million for potential ADCs SUZHOU, China and NEWTOWN SQUARE, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. , (“ArriVent”) a clinical-stage company dedicated to accelerating the... Read More

NEWTON SQUARE, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. , a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of John Hohneker, M.D. to its Board of Directors. Dr. Hohneker brings over 30 years of experience in biopharmaceutical leadership and drug development, and currently serves on the Boards of public... Read More

Presented preclinical firmonertinib (formerly furmonertinib) data at the 2024 American Association for Cancer Research (“AACR”) Annual Meeting Dosed first patient in Phase 1b combination study of firmonertinib and ICP-189 for advanced or metastatic non-small cell lung cancer (“NSCLC”) with epidermal growth factor receptor (“EGFR”) classical mutations Strong financial position with cash and cash equivalents of $317.4 million... Read More

NEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. , a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Kristine Peterson to its Board of Directors. Ms. Peterson brings over 30 years of biopharmaceutical leadership experience, and currently serves on the Boards of public companies Immunocore,... Read More

Company progresses the development of furmonertinib with a data readout planned for 2024 Furmonertinib granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration Completed $201 million initial public offering (“IPO”) in January 2024 NEWTOWN SQUARE, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“Company” or “ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to... Read More